Reviewer's report
Title:Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia,
phosphorylation of NMDA receptors, and cytokines expression in the thoracic
spinal dorsal horn
Version: 2Date:1 August 2012
Reviewer: Ihsan Ekin Demir
Reviewer's report:
In the revised version of their manuscript, Feng et al. extended their study by
additional experiments related to the role of resolvin D1 in pain-associated
behavior in chronic pancreatitis (CP). Here they observed that resolvin-D1
(RvD1) did not affect the behavior of animals in open-field and the elevated plus
maze tests. Additionally, they showed that RvD1 treatment significantly
suppressed the secretion of pro-inflammatory cytokines in the spinal cord of rats.
Overall, the study benefited significantly from these revisions. I have a single
major comment related to the current version of the study.
Major Compulsory Revisions
1) Pain continues to be an enigma not only in CP but in numerous neuropathic
pain disorders, and understanding its exact mechanism of generation bears
major importance. In the presence of several studies reporting on the beneficial
impact of several therapeutic agents on CP-related pain, it remains important to
demonstrate the cells upon which these agents act. Therefore, in my view,
showing this cell type by e.g. double immunolabeling as suggested before would
confer the study a very high quality. In particular, the authors should make use 1)
of a neuronal marker, 2) of a microglial marker, and 3) of an astrocyte marker to
show the site of RvD1 action.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Reviewer's report
Title:Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia,
phosphorylation of NMDA receptors, and cytokines expression in the thoracic
spinal dorsal horn
Version: 2Date:1 August 2012
Reviewer: Ihsan Ekin Demir
Reviewer's report:
In the revised version of their manuscript, Feng et al. extended their study by
additional experiments related to the role of resolvin D1 in pain-associated
behavior in chronic pancreatitis (CP). Here they observed that resolvin-D1
(RvD1) did not affect the behavior of animals in open-field and the elevated plus
maze tests. Additionally, they showed that RvD1 treatment significantly
suppressed the secretion of pro-inflammatory cytokines in the spinal cord of rats.
Overall, the study benefited significantly from these revisions. I have a single
major comment related to the current version of the study.
Major Compulsory Revisions
1) Pain continues to be an enigma not only in CP but in numerous neuropathic
pain disorders, and understanding its exact mechanism of generation bears
major importance. In the presence of several studies reporting on the beneficial
impact of several therapeutic agents on CP-related pain, it remains important to
demonstrate the cells upon which these agents act. Therefore, in my view,
showing this cell type by e.g. double immunolabeling as suggested before would
confer the study a very high quality. In particular, the authors should make use 1)
of a neuronal marker, 2) of a microglial marker, and 3) of an astrocyte marker to
show the site of RvD1 action.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Please review this paper.
user
Reviewer's report
Title:Resolvin D1 reverses chronic pancreatitis-induced mechanical allodynia,
phosphorylation of NMDA receptors, and cytokines expression in the thoracic
spinal dorsal horn
Version: 2Date:1 August 2012
Reviewer: Ihsan Ekin Demir
Reviewer's report:
In the revised version of their manuscript, Feng et al. extended their study by
additional experiments related to the role of resolvin D1 in pain-associated
behavior in chronic pancreatitis (CP). Here they observed that resolvin-D1
(RvD1) did not affect the behavior of animals in open-field and the elevated plus
maze tests. Additionally, they showed that RvD1 treatment significantly
suppressed the secretion of pro-inflammatory cytokines in the spinal cord of rats.
Overall, the study benefited significantly from these revisions. I have a single
major comment related to the current version of the study.
Major Compulsory Revisions
1) Pain continues to be an enigma not only in CP but in numerous neuropathic
pain disorders, and understanding its exact mechanism of generation bears
major importance. In the presence of several studies reporting on the beneficial
impact of several therapeutic agents on CP-related pain, it remains important to
demonstrate the cells upon which these agents act. Therefore, in my view,
showing this cell type by e.g. double immunolabeling as suggested before would
confer the study a very high quality. In particular, the authors should make use 1)
of a neuronal marker, 2) of a microglial marker, and 3) of an astrocyte marker to
show the site of RvD1 action.
Level of interest: An article of importance in its field
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
assistant